Atelvia (Risedronate Sodium Delayed-Release Tablets) Drug Information: Description, User Reviews, Drug Side Effects, Interactions

Pill Identifier Search

May 25, 2012

Atelvia

Osteoporosis »

Osteoporosis facts

Osteoporosis is a condition of increased susceptibility to fracture due to fragile bone.
Osteoporosis weakens bone and increases risk of bone fracture.
Bone mass (bone density) decreases after 35 years of age and decreases more rapidly in women after menopause.
Key risk factors for osteoporosis include genetics, lack of exercise, lack of calcium and vitamin D, personal history of fracture as an adult, cigarette smoking, excessive alcohol consumption, history of rheumatoid arthritis, low body weight, and family history of osteoporosis.
Patients with osteoporosis have no symptoms until bone fractures occur.
The diagnosis of osteoporosis can be suggested by X-rays and confirmed by tests to measure bone density.
Treatments for osteoporosis, in addition to prescription osteoporosis medications, include stopping use of alcohol and cigarettes, and assur...

Read the Osteoporosis article »

« Previous
1
2
3
4
5
6
7
8
9
10
Next »

Atelvia User Reviews >>

Atelvia

Osteoporosis Slideshow Pictures

Super Foods for Your Bones Slideshow Pictures

Take the Osteoporosis Quiz

font size

Atelvia™
(risedronate sodium) Delayed-Release Tablets

DRUG DESCRIPTION

Atelvia (risedronate sodium) delayed-release tablets contain a pH-sensitive enteric coating and a chelating agent (EDTA).

Risedronate is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. Each Atelvia (risedronate sodium delayed-release tablets) tablet for oral administration contains the equivalent of 35 mg of anhydrous risedronate sodium in the form of the hemi-pentahydrate with small amounts of monohydrate. The empirical formula for risedronate sodium hemi-pentahydrate is C7H10NO7P2Na •2.5 H2O. The chemical name of risedronate sodium is [1-hydroxy-2-(3pyridinyl)ethylidene]bis[phosphonic acid] monosodium salt. The chemical structure of risedronate sodium hemi-pentahydrate is the following:

Atelvia
(risedronate sodium) Structural Formula Illustration

Molecular Weight:
Anhydrous: 305.10
Hemi-pentahydrate: 350.13

Risedronate sodium is a fine, white to off-white, odorless, crystalline powder. It is soluble in water and in aqueous solutions, and essentially insoluble in common organic solvents.

Inactive Ingredients

Edetate disodium, ferric oxide yellow, magnesium stearate, methacrylic acid copolymer, polysorbate 80, silicified microcrystalline cellulose (ProSolv SMCC90), simethicone, sodium starch glycolate, stearic acid, talc, and triethyl citrate.

What are the precautions when taking risedronate sodium delayed-release tablets (Atelvia)?

Before taking risedronate, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney disease, inability to sit upright or stand for 30 minutes, low level of calcium in the blood (hypocalcemia), disorders of the esophagus (such as esophageal stricture or achalasia), difficult or painful swallowing, stomach/intestinal disorders (such as ulcers).

Infrequently, people taking this class of medication (bisphosphonates) have had serious jawbone problems (osteonecrosis). Lack of proper dental hygiene,...

Read All Potential Precautions of Atelvia »

Last reviewed on RxList: 11/4/2010
This monograph has been modified to include the generic and brand name in many instances.